RxDoctor Payments Data

Ilan Melnick

Psychiatry · Coral Gables, FLNPI 1427048115

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,063,240 of the $2,829,789 with a category attached, or 72.9%. 36 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 24.4% of the total. 2025 is the largest year on record at $813,000, 2.3 times the $347,546 reported in 2019. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,829,789in general payments, 2019–2025

Across 3,328 payments — averaging $850.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$690K
  • Neurocrine Biosciences, Inc.$655K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$339K
  • Teva Pharmaceuticals USA, Inc.$299K
  • Axsome Therapeutics, Inc.$204K
  • E.r. Squibb & Sons, L.L.C.$167K
  • plus $476K from 30 others

What the payments were for

  • Consulting fees$327,86212%
  • Speaking & faculty fees$2,063,24073%
  • Travel & lodging$366,18213%
  • Food & beverage$72,2533%
  • Education$2510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,829,789 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
UzedyRisperidone57$192,400
Austedo XrDeutetrabenazine18$162,997
Invega SustennaPaliperidone Palmitate26$77,608
RexultiBrexpiprazole31$45,257
AristadaAripiprazole Lauroxil13$41,469
OzempicSemaglutide31$38,673
EmsamSelegiline13$26,751
TrintellixVortioxetine Hydrobromide58$26,472
CaplytaLumateperone Tosylate12$20,606
SeroquelQuetiapine Fumarate17$14,974
Olanzapine OdtOlanzapine48$10,120
Fluphenazine Hcl36$10,048
Quetiapine Fumarate ErQuetiapine Fumarate47$9,743
Divalproex Sodium ErDivalproex Sodium76$8,281
Lamotrigine OdtLamotrigine12$7,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Uzedy, Austedo Xr$299,421$355,39775 claims
Johnson & JohnsonInvega Sustenna$1,266$77,60826 claims
Otsuka America Pharmaceutical, Inc.Rexulti$690,115$45,25731 claims
Alkermes, Inc.Aristada$157,250$41,46913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$9,750$26,47258 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$339,059$20,60612 claims
Eisai Inc.Dayvigo$10,902$4,65914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →